What is Sino Biopharmaceutical acquiring?

Sino Biopharmaceutical is acquiring Hangzhou Hygieia Biomedical, a China-based company focused on RNA therapies.

What is the value of the Sino Biopharmaceutical and Hygieia deal?

The deal is valued at up to 1.20 billion yuan, approximately $172.04 million.

What therapeutic areas does Hygieia focus on?

Hygieia's research is focused on weight management, metabolism, cardiovascular, cerebrovascular diseases, and neurological disorders.

Home / Business and Economy / Sino Biopharm Buys RNA Drug Developer Hygieia

Sino Biopharm Buys RNA Drug Developer Hygieia

13 Jan

•

Summary

Sino Biopharmaceutical will acquire Hangzhou Hygieia for up to 1.20 billion yuan.
The deal aims to expand Sino Biopharmaceutical's chronic disease treatment portfolio.
Hygieia specializes in small interfering RNA therapies for metabolism and neurological disorders.

Sino Biopharm Buys RNA Drug Developer Hygieia

Sino Biopharmaceutical has announced its intent to acquire Hangzhou Hygieia Biomedical for a maximum of 1.20 billion yuan, approximately $172.04 million. This acquisition, finalized on Tuesday, January 13, 2026, is a key step in bolstering the company's offerings in chronic-disease treatments.

The deal involves a unit of Sino Biopharmaceutical purchasing a 100% stake in Hygieia. Consideration will be a mix of cash and newly issued shares, making Hygieia a subsidiary. This follows Sino Biopharmaceutical's recent expansion into innovative drug pipelines, including a prior agreement with LaNova Medicines.

Hygieia is recognized for its development of small interfering RNA therapies, possessing a comprehensive platform from target discovery to clinical proof-of-concept. The company's research is particularly focused on critical areas such as weight management, metabolism, cardiovascular and cerebrovascular diseases, and neurological disorders.